Nevirapine toxicity - implications for management of South African patients

Journal Article

2005

Permanent link to this Item
Authors
Journal Title

South African Medical Journal

Journal ISSN
Volume Title
Publisher
Publisher
License
Series
Abstract
Nevirapine was the first non-nucleoside drug (NNRTI) to be approved by the Federal Drug Administration (FDA) for use in combination therapy of HIV-1 infection in 1996. It has been approved for use in children of 2 months or older, and following the publication of the HIVNET 012 study in Uganda1 has been widely used as single-dose prophylaxis for prevention of mother-to-child HIV transmission (MTCT) in resource-poor settings. Early in nevirapine development, a cutaneous hypersensitivity rash occurring in the first 4 weeks of therapy was recognised as a common side-effect, and registration studies reported clinical hepatitis in approximately 1% of individuals.2 Despite these recognised toxicities, cheap generic formulations, including fixed-dose combinations, have been manufactured in India and Brazil, making nevirapine one of the most commonly prescribed antiretrovirals worldwide.
Description

Reference:

Collections